Free Trial

Eton Pharmaceuticals Q1 2023 Earnings Report

Eton Pharmaceuticals logo
$13.74 -1.05 (-7.10%)
As of 03/25/2025 04:00 PM Eastern

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
$5.30 million
Expected Revenue
$4.60 million
Beat/Miss
Beat by +$700.00 thousand
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Eton Pharmaceuticals Earnings Headlines

HC Wainwright Analysts Lower Earnings Estimates for ETON
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Research Analysts Set Expectations for ETON Q3 Earnings
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

View Eton Pharmaceuticals Profile

More Earnings Resources from MarketBeat